VisionGate is a leading biotechnology company based in Phoenix, AZ, dedicated to fighting lung cancer in high-risk patients through innovative non-invasive testing methods. Their breakthrough technology utilizes 3D cell imaging and an AI-powered cancer detection process, allowing for early detection of lung cancer using simple sputum samples. With a strong intellectual property portfolio and a focus on early detection, VisionGate is at the forefront of novel science in the battle against lung cancer.
Through their patented Cell-CT imaging, VisionGate is able to analyze hundreds of disease indicators and molecular markers in individual cells, providing valuable insights for early diagnosis. Their non-intrusive testing approach, which involves collecting sputum samples over a three-day period, offers a quick and efficient way to detect lung cancer well before other methods can detect anything. With a commitment to saving lives through early detection, VisionGate is revolutionizing the fight against lung cancer.
Generated from the website